Welcome to our dedicated page for Alumis SEC filings (Ticker: ALMS), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Alumis Inc. filings document material events for a Nasdaq-listed biopharmaceutical issuer, including 8-K reports on clinical data, corporate presentations, operating and financial results and capital-structure activity. The disclosures identify common stock listed under ALMS on The Nasdaq Global Select Market and note the company’s emerging growth company status.
The filing record covers envudeucitinib presentations and press releases, financial-results exhibits, common-stock offering disclosures, and shareholder voting matters from the annual meeting and proxy process. These documents frame the company’s governance, material agreements, capital structure and clinical or regulatory disclosure around its TYK2 inhibitor pipeline.
Alumis Inc. Chief Medical Officer Jorn Drappa exercised stock options to acquire 26,852 shares of common stock. The Form 4 shows two option exercises on May 22, 2026, covering 15,535 shares at an exercise price of $5.06 per share and 11,317 shares at $8.84 per share. All transactions are coded as exercises of derivative securities, with no open-market purchases or sales reported in this filing.
Alumis Inc. is asking stockholders to vote at its 2026 virtual annual meeting on June 30, 2026. Stockholders will elect three Class II directors to serve until the 2029 annual meeting and vote on ratifying PricewaterhouseCoopers LLP as independent auditor for fiscal 2026.
The meeting is online only via live audio webcast, with a record date of May 5, 2026. Alumis describes its classified board structure, independence determinations under Nasdaq rules, committee composition, and governance policies, including a lead independent director role and an insider trading policy that prohibits hedging and pledging of company stock.
Alumis Inc. reports Q1 2026 results showing it remains a clinical-stage company investing heavily in R&D while strengthening its balance sheet. Total revenue was $1.7 million, mainly from collaboration revenue, while net loss narrowed slightly to $93.1 million, or $0.74 per share, versus a $99.0 million loss a year earlier.
R&D expenses were $81.5 million and G&A expenses were $18.6 million, reflecting ongoing development programs and integration of the ACELYRIN merger. Alumis closed a January 2026 public equity offering, receiving $324.4 million in net proceeds, and ended March 31, 2026 with $569.5 million in cash, cash equivalents and marketable securities and total assets of $671.6 million.
The company maintains an accumulated deficit of $994.9 million and continues to expect substantial losses as it develops autoimmune therapies, but believes its current cash resources will fund operating and capital needs for at least 12 months from the financial statement issuance date. An at-the-market facility permits up to $300.0 million in additional stock sales, with no shares sold as of March 31, 2026.
Alumis Inc. reported first quarter 2026 results and highlighted strong Phase 3 data for its oral TYK2 inhibitor envudeucitinib in moderate-to-severe plaque psoriasis. For the quarter ended March 31, 2026, total revenue was $1,741 (in thousands) compared with $17,389 (in thousands) a year earlier, with a net loss of $93,053 (in thousands) versus $98,963 (in thousands).
The Phase 3 psoriasis study showed robust skin clearance, with PASI 90 responses of 68.0% and 62.1% and PASI 100 responses of 41.0% and 39.5% at Week 24, along with improvements in quality of life and symptoms. Alumis plans to submit a New Drug Application for envudeucitinib in plaque psoriasis in the fourth quarter of 2026 and anticipates potentially pivotal Phase 2b topline data in systemic lupus erythematosus in the third quarter of 2026. Cash, cash equivalents and marketable securities contributed to total assets of $671,588 (in thousands) as of March 31, 2026.
ALUMIS Inc. Schedule 13G: Deep Track Capital, Deep Track Biotechnology Master Fund and David Kroin report beneficial ownership of 7,362,035 shares of Common Stock, representing 5.98% of the class as of April 7, 2026.
The filing cites 123,139,425 shares outstanding as of March 12, 2026 (per the issuer's 10-K). Ownership is reported as shared voting and dispositive power of 7,362,035 shares by the reporting persons.
ALUMIS INC. insider filing shows internal share transfers among Foresite-affiliated entities, not market trades. Foresite Labs Affiliates 2021, LLC and Foresite Labs, LLC reported Form 4 transactions coded "J" in Common Stock on April 1, 2026, described as other acquisitions or dispositions.
Footnotes explain these were pro rata, in-kind distributions without additional consideration under Exchange Act Rules 16a-13 and 16a-9, rather than purchases or sales. Shares were distributed between entities such as Foresite Labs Affiliates 2021, LLC, Foresite Labs, LLC, and TFL Investment Holdings, LLC, with various Foresite funds and co-invest vehicles holding record ownership.
The reporting persons and related entities note that voting and dispositive power over the shares may be attributed to managing LLCs and to James B. Tananbaum in his roles, while explicitly disclaiming group status and beneficial ownership beyond any pecuniary interest.
ALUMIS INC. reported a Form 4 showing internal equity restructurings by entities associated with Foresite Capital and Foresite Labs, rather than open-market trading. On April 1, 2026, several J-code transactions moved blocks of common stock through pro rata, in-kind distributions for no cash consideration.
Labs Affiliates made in-kind distributions of shares to its members, including Foresite Labs, LLC, which then distributed shares on a pro rata basis to its own members, such as TFL Investment Holdings, LLC. Additional indirect holdings are reported for Foresite Capital Fund V, Opportunity Fund V, Fund VI, Labs Co-Invest V and Foresite Labs Fund I, all with voting and dispositive power described in the footnotes and subject to customary beneficial ownership disclaimers.
ALUMIS INC. director and 10% owner James B. Tananbaum reported a series of internal restructurings of 4,103,630 shares of common stock, coded as "J" transactions. The shares moved through pro rata, in-kind distributions among affiliated entities for no consideration and not as open-market purchases or sales.
The filing shows indirect holdings across several Foresite and Labs-related funds and LLCs, with post-transaction positions such as 5,702,536, 2,908,332, 4,247,670, 194,459 and 1,960,337 shares held of record by these entities. Tananbaum may share voting and dispositive power but consistently disclaims group status and beneficial ownership beyond his pecuniary interest.
Alumis Inc. shareholder Foresite-affiliated funds and James B. Tananbaum filed Amendment No. 4 to update their Schedule 13D. The filing reflects pro rata distributions by Foresite Labs Affiliates 2021, LLC and Foresite Labs, LLC, which reduced their Alumis common stock holdings to zero.
After these changes, James B. Tananbaum is reported to beneficially own 15,693,820 shares of Alumis common stock, representing 12.7% of the outstanding shares as of March 12, 2026. Individual Foresite funds continue to hold significant stakes, with sole voting and dispositive power attributed through their respective general partners and management entities.
The reporting group, active in venture capital investing in life sciences and healthcare, states it holds Alumis shares for investment purposes and may buy, sell, or distribute shares over time based on market conditions and its ongoing assessment of the company.